FDA Approves Rextovy, Adding Third Over-the-Counter Naloxone Option to Combat Opioid Overdoses

The Food and Drug Administration has approved Rextovy, a new over-the-counter naloxone nasal spray, marking the third such product to become available without a prescription as federal regulators continue expanding access to the life-saving medication.

The 4-milligram formulation, manufactured by Amphastar Pharmaceuticals, joins Narcan and RiVive as nonprescription options for reversing opioid overdoses. The approval arrives as the United States records a third consecutive year of declining overdose deaths, a trend public health officials attribute partly to the wider availability of naloxone in communities hardest hit by the opioid crisis.

Expanding the Arsenal Against Overdose Deaths

Naloxone has emerged as one of the most effective tools in reducing opioid mortality over the past decade. The medication works by rapidly displacing opioids from brain receptors, restoring normal breathing within minutes when administered during an overdose. Its effectiveness has made broad distribution a cornerstone of harm reduction strategies nationwide.

The FDA's decision to approve Rextovy reflects a deliberate strategy to increase market competition and reduce barriers to access. "Reducing opioid overdose deaths is a top priority for FDA," said Dr. Mike Davis, acting director of the FDA's Center for Drug Evaluation and Research, in announcing the approval. "Today's approval of an additional over-the-counter naloxone nasal spray helps broaden access and offers an additional option for consumers."

The agency emphasized that empowering people without medical training to take immediate action has proven effective at saving lives. Rextovy's packaging includes pictorial directions with five clear steps, including calling emergency services after administering the first dose.

Building on Momentum as Deaths Decline

The approval comes amid encouraging trends in overdose mortality. According to Trust for America's Health, fatal drug overdoses dropped 26% between 2023 and 2024, representing the most sustained decline in decades. The CDC documented approximately 68,632 overdose deaths in the twelve-month period ending December 2025, down significantly from peak levels.

Yet the crisis remains acute. Synthetic opioids, primarily illicit fentanyl, continue driving the majority of fatalities. The emergence of medetomidine—a veterinary tranquilizer increasingly mixed into fentanyl supplies—has complicated overdose response, as the sedative can prolong unconsciousness even after naloxone restores breathing.

Dr. Anita Gupta, a pain management specialist and former FDA advisor, called the expansion of over-the-counter naloxone "an absolute game changer." In comments to Healio Primary Care, she noted that community access to nonprescription naloxone has been "undeniably one of the primary engines that have decreased fatalities."

"I really believe this proves that when you put life-saving innovation and tools into the hands of the public, fewer people die," Gupta said.

Market Competition and Accessibility

The entry of a third manufacturer into the over-the-counter naloxone market carries significant implications for pricing and distribution. Narcan, approved in September 2023, and RiVive, approved in July 2023, established the commercial viability of nonprescription overdose reversal medication. Rextovy's approval introduces additional competition that could drive down costs and expand availability in retail pharmacies, convenience stores, and online marketplaces.

The FDA specifically noted that multiple approved products "expands access and market availability, encourages competition that may reduce cost, and offers alternative sourcing options" for community distribution programs.

For individuals witnessing an overdose, Rextovy works similarly to existing products. The nasal spray delivers naloxone hydrochloride directly through the nasal mucosa, where it rapidly enters the bloodstream and travels to the brain. Users may observe the person experiencing withdrawal symptoms—shaking, nausea, sweating, or agitation—as the opioids are displaced and consciousness returns.

The FDA confirmed that the product is safe to use even when uncertain whether opioids are present, addressing concerns that bystanders might hesitate to administer naloxone due to uncertainty about the cause of unconsciousness.

Policy Context and Future Directions

The Rextovy approval aligns with the Trump administration's Great American Recovery Initiative, which has emphasized expanding access to overdose reversal medications while simultaneously shifting federal policy away from some harm reduction strategies. The administration recently directed health programs to deprioritize housing-first approaches and certain harm reduction services, even as it supports naloxone distribution.

This tension reflects broader debates about the most effective approaches to reducing overdose deaths. While naloxone access enjoys bipartisan support, disagreements persist about the role of supervised consumption sites, syringe exchange programs, and medication-assisted treatment in addressing the crisis.

For now, the approval of a third over-the-counter naloxone product represents incremental progress in making overdose reversal medication as accessible as possible. With approximately 120 Americans still dying from opioid overdoses daily according to Senator Ed Markey's office, the expansion of naloxone availability addresses one critical piece of a complex public health challenge.

Community organizations, first responders, and public health departments will likely incorporate Rextovy into existing distribution networks alongside Narcan and RiVive. The presence of multiple manufacturers may also provide resilience against supply disruptions and create opportunities for bulk purchasing that could stretch limited public health budgets further.

As the drug supply continues evolving—with new synthetic opioids and adulterants appearing regularly—the availability of multiple naloxone formulations ensures that communities have options for responding to overdoses. While naloxone alone cannot address the root causes of addiction, its proven ability to prevent death creates the essential foundation upon which treatment and recovery can build.